Next Article in Journal
Human Chorionic Gonadotropin Beta Subunit Genes CGB1 and CGB2 are Transcriptionally Active in Ovarian Cancer
Next Article in Special Issue
Effects of Calorie Restriction and IGF-1 Receptor Blockade on the Progression of 22Rv1 Prostate Cancer Xenografts
Previous Article in Journal
Quorum Sensing and Phytochemicals
Previous Article in Special Issue
Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
Open AccessReview

The Present and Future of Prostate Cancer Urine Biomarkers

1
Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, 08035 Barcelona, Spain
2
Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, 08035 Barcelona, Spain
3
Department of Pathology, Vall d'Hebron University Hospital Autonomous University of Barcelona, 08035 Barcelona, Spain
4
Cancer Genetics, University of East Anglia, Norwich Norfolk, NR4 7TJ, UK
5
Department of Basic Sciences, International University of Catalonia, 08017 Barcelona, Spain
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2013, 14(6), 12620-12649; https://doi.org/10.3390/ijms140612620
Received: 23 April 2013 / Revised: 27 May 2013 / Accepted: 3 June 2013 / Published: 17 June 2013
(This article belongs to the Special Issue Molecular Research in Urology)
In order to successfully cure patients with prostate cancer (PCa), it is important to detect the disease at an early stage. The existing clinical biomarkers for PCa are not ideal, since they cannot specifically differentiate between those patients who should be treated immediately and those who should avoid over-treatment. Current screening techniques lack specificity, and a decisive diagnosis of PCa is based on prostate biopsy. Although PCa screening is widely utilized nowadays, two thirds of the biopsies performed are still unnecessary. Thus the discovery of non-invasive PCa biomarkers remains urgent. In recent years, the utilization of urine has emerged as an attractive option for the non-invasive detection of PCa. Moreover, a great improvement in high-throughput “omic” techniques has presented considerable opportunities for the identification of new biomarkers. Herein, we will review the most significant urine biomarkers described in recent years, as well as some future prospects in that field. View Full-Text
Keywords: prostate cancer; biomarker; urine; non-invasive prostate cancer; biomarker; urine; non-invasive
MDPI and ACS Style

Rigau, M.; Olivan, M.; Garcia, M.; Sequeiros, T.; Montes, M.; Colás, E.; Llauradó, M.; Planas, J.; De Torres, I.; Morote, J.; Cooper, C.; Reventós, J.; Clark, J.; Doll, A. The Present and Future of Prostate Cancer Urine Biomarkers. Int. J. Mol. Sci. 2013, 14, 12620-12649.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop